Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
11 hedge funds and large institutions have $6.77M invested in Aptose Biosciences, Inc. in 2015 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0.62% less ownership
Funds ownership: 14.6% → 13.97% (-0.62%)
8% less funds holding
Funds holding: 12 → 11 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
89% less capital inflows, than outflows
Capital inflows: $61.9K | Capital outflows: $569K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Callan Capital
La Jolla,
California
|
+$47.8K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.6K |
| 3 |
Punch & Associates Investment Management
Edina,
Minnesota
|
+$1.77K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$179K |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
-$125K |
| 3 |
Weiss Multi-Strategy Advisers
New York
|
-$108K |
| 4 |
DAFNA Capital Management
Los Angeles,
California
|
-$83K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$42.5K |
APTO Hedge Fund Activity: Q4 2015 in Review
11 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q4 2015, worth a combined $6.77M — down 43% from $12M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of APTO and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Callan Capital, opening a new position worth an estimated $47.8K. The largest seller was BVF Inc, exiting entirely with an estimated $179K sold.
- 11 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q4 2015, down from 12 in Q3 2015.
- Funds reported $6.77M of Aptose Biosciences, Inc. stock for Q4 2015, down 43% quarter-over-quarter.
- 3 funds opened new Aptose Biosciences, Inc. positions in Q4 2015 and 4 closed out, a net change of -1 holder.
- The largest Aptose Biosciences, Inc. buyer in Q4 2015 was Callan Capital, an estimated $47.8K added.
- The largest Aptose Biosciences, Inc. seller in Q4 2015 was BVF Inc, an estimated $179K sold.
Based on aggregated 13F filings for Q4 2015.